You are here: Industry Insights > fibrosis

News List

Aramchol™ reduces fibrosis progression in 24 weeks EuropeanPharmaceuticalReview
November 02, 2021
Galmed Pharmaceuticals has announced results from the first 16 patients in the open-label part of the ARMOR Phase III study who underwent a scheduled post-baseline biopsy and were treated with Aramchol™ for fibrosis.
Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs prnasia
January 19, 2021
Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in ...
Galapagos expands fibrosis research collaboration with Fibrocor pharmaceutical-technology
January 17, 2020
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
Galmed Initiated Study of Aramchol in Subjects with NASH and Fibrosis americanpharmaceuticalreview
September 27, 2019
Galmed Pharmaceuticals announced the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled ...
Key Cystic Fibrosis Pathogens Reduced With Ivacaftor Use drugs
July 22, 2019
For patients with cystic fibrosis (CF), ivacaftor use is associated with a reduction in pathogens, including Pseudomonas aeruginosa...
FDA Expands Cystic Fibrosis Treatment Approval for Symdeko (Tezacaftor/ivacaftor) to Children Ages 6 to 12 drugs
June 25, 2019
FDA Expands Cystic Fibrosis Treatment Approval for Symdeko (Tezacaftor/ivacaftor) to Children Ages 6 to 12.
FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12 drugs
June 24, 2019
FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12.
An Antibiotic Alternative? Using a Virus to Fight Bacteria drugs
May 09, 2019
An Antibiotic Alternative? Using a Virus to Fight Bacteria.
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis worldpharmanews
March 19, 2019
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib
Evotec and Galapagos collaborate for new fibrosis target pharmaceutical-technology
February 20, 2019
German biotechnology company Evotec has entered into a collaboration agreement with Belgo-Dutch pharmaceutical firm Galapagos for a new, undisclosed target to treat fibrosis....

Previous page 1 2 Next page